Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2026 · 10-Q
Revenue$199.88M$199.88M+6.3% vs Q2 2025 Net Income-$15.05M-$15.05MN/M vs Q2 2025 EPS Diluted-$0.46-$0.46N/M vs Q2 2025 Gross Profit$110,292,000+1.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$71,323,000−1.5% Free Cash Flowderived$70,827,000−2.1% Margins · derivedGross margin55.2%−2.5 pt vs Q2 2025
Operating margin1.9%−16.8 pt vs Q2 2025
Net margin-7.5%−13.9 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end